Citius aims Q4 2025 LYMPHIR launch but faces cash runway only through Sept 2025

Company: Citius Pharmaceuticals, Inc. (NASDAQ: CTXR)

What's happening inside the company
- Citius is transitioning from development to commercial stage - FDA-approved LYMPHIR (denileukin diftitox) (approval Aug 8, 2024) and preparing a U.S. commercial launch targeted for Q4 2025.
- The majority-owned subsidiary Citius Oncology (92.3% owned) is the vehicle for LYMPHIR commercialization; distribution agreements with Cardinal Health and Cencora announced to support the launch.
- Management is raising capital actively (multiple registered/direct offerings and ATM sales in fiscal 2025) and has taken on short-term debt (note payable $1.0M at 15%).
- Company flagged a going-concern uncertainty: available cash is expected to fund operations only through September 2025 without additional financing or subsidiary financings.

Key financial facts & figures (as reported at June 30, 2025)
- Cash and cash equivalents: $6,089,126 (up from $3,251,880 at Sept 30, 2024).
- Inventory: $17,208,967 (finished goods $8,962,493; WIP $8,246,474) - built for LYMPHIR commercialization (vs $8,268,766 prior).
- Total assets: $127,676,859; Total liabilities: $60,115,929; Stockholders' equity: $67,560,930.
- Negative working capital ≈ $27.2 million at June 30, 2025.
- Revenues: $0 for both quarter and nine-month periods (no product sales yet).
- Net loss (three months ended June 30, 2025): $9,203,872; Net loss (nine months): $30,996,623.
- Operating expenses (Q3): $8,788,007 - R&D $1,621,325; G&A $4,447,008; stock-based comp (G&A) $2,719,674.
- Net loss per share (basic & diluted): Q3 $(0.80); nine months $(3.27). Weighted average shares - nine months: 9,020,356.
- License payable (current): $28,400,000; deferred tax liability: $7,506,520.
- Material manufacturing minimum purchase commitments: ~$18.3M (drug substance) + ~$4.5M (packaging) across 2025-2026.
- Subsequent actions: regained Nasdaq $1.00 compliance on July 8, 2025; additional equity financing activity by Citius Oncology in July 2025 (gross ≈ $9.0M offering).

Positive aspects of the income statement & balance sheet
- R&D expense down (nine months) as late-stage clinical programs complete and focus shifts to commercialization - frees resources for launch activities.
- Inventory build demonstrates operational progress toward commercial supply for LYMPHIR - necessary step before revenue generation.
- Management raised meaningful equity proceeds in 2025 (net proceeds from offerings and ATM activity helped increase cash balance vs prior year).
- Stock-based compensation declined year-over-year, reducing a non-cash operating expense component.

Negative aspects of the income statement & balance sheet
- No revenue to offset expenses - company remains loss-making (net loss ~ $31M YTD) and dependent on financing.
- Large current liabilities and license payables (including milestone obligations) create significant near-term cash demands (e.g., $22.5M balance related to Dr. Reddy's milestone outstanding as of June 30, 2025).
- Negative working capital (~$27.2M) and stated cash runway only through September 2025 without new financing - material going-concern risk.
- Interest expense and financing costs are rising (note payable at 15% and interest under payment agreements).
- Heavy commitments to contract manufacturing (minimum purchase obligations) create cash outflow pressure before product revenue ramps.
- Continued dilution risk: multiple equity raises and many warrants/pre-funded warrants outstanding (17.6M warrants reserved) - potential share count expansion if exercised.

Short, straight takeaway for investors
- Citius (NASDAQ: CTXR) is at an inflection point: it has an FDA-approved product (LYMPHIR) and distribution partners in place, inventory built for a planned Q4 2025 U.S. launch - all clear positives for future revenue potential.
- But the company has not generated revenue yet, is burning cash, carries large milestone and manufacturing obligations, and reports a tight cash runway (management says through Sept 2025 unless additional funding is secured).
- Near-term share-price catalysts: successful Q4 2025 launch execution, initial LYMPHIR sales, and additional financings (or Citius Oncology capital raises). Key near-term risks: failure to secure financing on acceptable terms, missed milestone payments, or launch delays.

If you want, I can: (1) produce a short cash-runway and financing-scenario model, or (2) summarize upcoming milestones and dates to watch for CTXR/Citius Oncology.